Anti‑C1q Antibody Testing and Clinical Management in Systemic Lupus Erythematosus

When to Test Anti‑C1q Antibodies

Active lupus nephritis – Anti‑C1q antibodies are detected in almost 100 % of patients with active renal involvement, providing a highly sensitive marker for lupus nephritis. 1
Established lupus nephritis – A negative anti‑C1q result carries a strong negative predictive value, indicating a low likelihood of imminent renal flare. 2
Anti‑dsDNA–negative SLE with renal disease – In patients lacking anti‑dsDNA antibodies despite lupus nephritis, anti‑C1q serves as an alternative serologic biomarker. 4
Overall prevalence – Anti‑C1q antibodies are present in 30–60 % of all SLE patients and increase markedly in those with active renal disease. 3

Correlation with other autoantibodies – Anti‑C1q titers rise in parallel with anti‑dsDNA levels and inversely with complement components (C3, C4, CH50). 1
Predicting renal flares – The assay’s high negative predictive value makes the absence of anti‑C1q a reliable indicator of low short‑term flare risk. 3

Assess for active nephritis – Prompt evaluation for proteinuria (>0.5 g/day), hematuria, and worsening renal function is recommended. (Guideline‑based, no specific citation needed)
Renal biopsy – Consider a repeat biopsy when clinical suspicion persists or response to therapy is inadequate. 5

Baseline SLE therapy (EULAR) – Hydroxychloroquine is advised for all SLE patients, with glucocorticoid doses kept below 7.5 mg/day. Positive anti‑C1q in active nephritis may necessitate escalation to immunosuppressants such as methotrexate, azathioprine, or mycophenolate. 6 – Guideline recommendation
Biologic options for refractory disease – Belimumab can be used for persistent extrarenal activity, while rituximab is appropriate for organ‑threatening, refractory manifestations. 7 – Guideline recommendation
Standard induction for confirmed nephritis – Mycophenolate mofetil or cyclophosphamide combined with glucocorticoids remains the cornerstone of induction therapy. 5

Serial anti‑C1q measurements – Levels typically decline after successful treatment and correlate with changes in disease activity scores (SLEDAI). 1 – Observational evidence
Combined serologic follow‑up – Ongoing monitoring should include anti‑dsDNA and complement assays alongside anti‑C1q, as endorsed by expert consensus. 9 – Consensus recommendation
Serologically active but clinically quiescent disease – Some patients maintain positive anti‑C1q (and other serologies) without overt clinical activity, underscoring the need for comprehensive assessment. 2 – Observational evidence